Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 2020-2026

  McCloskey, Manabu ^a   Wang, Haibo ^a   Jiang, Yanchao ^a   Smith, George Wesley ^a   Strange, Jeremy ^a   Elizabeth Hartnett, M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; ERYTHROPOIETIN; PROTEIN P18; PROTEIN P25; STAT3 PROTEIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; WESTERN BLOTTING;

EID: 84875446268     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11625     Document Type: Article

References (33)

1. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116: 1599-1603.
2. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. NEngl J Med. 2012;367:2515-2526.
3. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010;120:3033-3041.
4. Nicholson B, Schachat A. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
5. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3{thorn} retinopathy of prematurity. N Engl J Med. 2011;364:603-615.
6. Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130:801-802.
7. Mititelu M, Chaudhary KM, Lieberman RM. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2012;1-9.
8. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev. 2012;88:937-941.
9. Hu J. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000-1006.
10. Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5 [published online ahead of print December 25, 2012]. Arch Dis Child Fetal Neonatal Ed. doi:10.1136/archdischild-2012-302365.
11. Sone H, Kawakami Y, Kumagai AK, et al. Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy. Life Sci. 1999;65:2573-2580.
12. Geisen P, Peterson L, Martiniuk D, Uppal A, Saito Y, Hartnett M. Neutralizing antibody to VEGF reduces intravitreous neovascularization and does not interfere with vascularization of avascular retina in an ROP model. Mol Vis. 2008;14:345-357.
13. Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res. 2009;89:718-727.
14. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49:522-527.
15. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36:724-731.
16. Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. Lancet. 1995;346:1464-1465.
17. Holmes JM, Duffner LA. The effect of postnatal growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat. Curr Eye Res. 1996;15:403-409.
18. Wang H, Byfield G, Jiang Y, Smith GW, McCloskey M, Hartnett ME. VEGF-mediated STAT3 activation inhibits retinal vascularization by downregulating erythropoietin expression. Am J Pathol. 2012;180:1243-1253.
19. Roberto KA, Tolman BL, Penn JS. Long-term retinal vascular abnormalities in an animal model of retinopathy of prematurity. Curr Eye Res. 1996;15:932-937.
20. Rapisarda A, Shoemaker RH, Melillo G. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle. 2009;8: 4040-4043.
21. Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. 2012; 118:3455-3467.
22. Bullard LE, Qi X, Penn JS. Role for extracellular signalresponsive kinase-1 and 2 in retinal angiogenesis. Invest Ophthalmol Vis Sci. 2003;44:1722-1731.
23. Brown MS, Eichorst D, LaLa-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics. 2009;124:e681-e687.
24. Byfield G, Budd S, Hartnett ME. Supplemental oxygen can cause intravitreous neovascularization through JAK/STAT pathways in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2009;50:3360-3365.
25. Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol. 2006;124:24-30.
26. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe GA. Change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116:513-518.
27. Uno K, Merges CA, Grebe R, Lutty GA, Prow TW. Hyperoxia inhibits several critical aspects of vascular development. Dev Dyn. 2007;236:981-990.
28. Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME. Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci. 2008;49:1591-1598.
29. Morita M, Ohneda O, Yamashita T, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003;22:1134-1146.
30. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LEH. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009;50:1329-1335.
31. Suk KK, Dunbar JA, Liu A, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS. 2008;12:233-238.
32. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327-333.
33. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygeninduced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;52:4039-4047.